ArticleClinical, cosmetic and investigational dermatology2026
Safety and Feasibility of Compound Glycyrrhizin-Based Combination Therapy for Coexisting Facial Vitiligo and Melasma: A Real-World Retrospective Study.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The coexistence of vitiligo and melasma poses a therapeutic challenge, as interventions for one condition may adversely affect the other. Compound glycyrrhizin (CG), an immunomodulatory agent widely used in vitiligo management in China, has been explored in combination treatment strategies. However, data on its use in patients concurrently affected by melasma are limited. Methods: This retrospective analysis included 29 adults with facial non-segmental vitiligo and coexisting melasma who received oral CG for 12 months, in combination with topical tacrolimus and phototherapy using melasma shielding. Clinical parameters were evaluated using the Facial Vitiligo Area Scoring Index (F-VASI) and Melasma Area and Severity Index (MASI), along with standardized facial photography and serum chemokine profiling. Results: Among the 29 patients who underwent combination therapy, the mean baseline F-VASI was 0.99 ± 0.65, which decreased by 54.93% ± 19.99% over 12 months. Initial repigmentation was observed at a mean of 4.17 ± 1.26 months. Melasma severity remained largely stable throughout the treatment period (baseline MASI 16.51 ± 7.31 vs 15.97 ± 7.02 post-treatment). In parallel, serum CXCL10 and CCL20 levels showed a downward trend over time, coinciding with clinical improvement. Conclusion: In this retrospective real-world cohort, facial vitiligo improved during 12 months of CG-based combination therapy without apparent worsening of coexisting melasma. The regimen was well tolerated, with no severe adverse events. Controlled studies are needed to confirm efficacy and clarify the independent role of CG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.